Equity Analysis /
United States of America

US : Amneal Pharmaceuticals Inc. - AMRX | 3Q21 Results — Strong New Product Dynamics But Generic Headwinds Challenge Top Line Momentum

    Michael Parolari
    Michael Parolari

    Research Associate

    CGS-CIMB
    3 November 2021
    Published by